Complement in immune and inflammatory disorders: Pathophysiological mechanisms

Journal of Immunology

Volumn 190, Issue 8, 2013, Pages 3831-3838

  Ricklin, Daniel ^a   Lambris, John D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT COMPONENT C5A RECEPTOR ANTAGONIST; COMPLEMENT COMPONENT C5B; ECULIZUMAB; IMMUNOMODULATING AGENT; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIBODY RESPONSE; CANCER GROWTH; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; DEGENERATIVE DISEASE; DISEASE ACTIVITY; DISEASE COURSE; GRAFT REJECTION; HEMOLYTIC UREMIC SYNDROME; HOST CELL; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFLAMMATORY DISEASE; MALIGNANT NEOPLASTIC DISEASE; NEUROMODULATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; TISSUE INJURY;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HOMEOSTASIS; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNITY, INNATE; INFECTION; INFLAMMATION;

EID: 84875968524     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1203487     Document Type: Review

References (85)

1. Ricklin, D., G. Hajishengallis, K. Yang, and J. D. Lambris. 2010. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11: 785-797.
2. Leslie, M. 2012. Immunology: the new view of complement. Science 337: 1034-1037.
3. de Cordoba, S. R., A. Tortajada, C. L. Harris, and B. P. Morgan. 2012. Complement dysregulation and disease: from genes and proteins to diagnostics and drugs. Immunobiology 217: 1034-1046.
4. Ricklin, D., and J. D. Lambris. 2013. Progress and trends in complement therapeutics. Adv. Exp. Med. Biol. 734: 1-22.
5. Markiewski, M. M., and J. D. Lambris. 2007. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am. J. Pathol. 171: 715-727.
6. Ricklin, D., and J. D. Lambris. 2013. Complement in immune and inflammatory disorders: therapeutic interventions. J. Immunol. 190: 3839-3847.
7. Nilsson, B., and K. Nilsson Ekdahl. 2012. The tick-over theory revisited: is C3 a contact-activated protein? Immunobiology 217: 1106-1110.
8. Forneris, F., D. Ricklin, J. Wu, A. Tzekou, R. S. Wallace, J. D. Lambris, and P. Gros. 2010. Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science 330: 1816-1820.
9. Hourcade, D., M. K. Liszewski, M. Krych-Goldberg, and J. P. Atkinson. 2000. Functional domains, structural variations and pathogen interactions of MCP, DAF and CR1. Immunopharmacology 49: 103-116.
10. Doni, A., C. Garlanda, B. Bottazzi, S. Meri, P. Garred, and A. Mantovani. 2012. Interactions of the humoral pattern recognition molecule PTX3 with the complement system. Immunobiology 217: 1122-1128.
11. Kemper, C., J. P. Atkinson, and D. E. Hourcade. 2010. Properdin: emerging roles of a pattern-recognition molecule. Annu. Rev. Immunol. 28: 131-155.
12. Klos, A., A. J. Tenner, K. O. Johswich, R. R. Ager, E. S. Reis, and J. Köhl. 2009. The role of the anaphylatoxins in health and disease. Mol. Immunol. 46: 2753-2766.
13. Degn, S. E., J. C. Jensenius, and M. Bjerre. 2010. The lectin pathway and its implications in coagulation, infections and auto-immunity. Curr. Opin. Organ Transplant. 16: 21-27.
14. Schwaeble, W. J., N. J. Lynch, J. E. Clark, M. Marber, N. J. Samani, Y. M. Ali, T. Dudler, B. Parent, K. Lhotta, R. Wallis, et al. 2011. Targeting of mannanbinding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc. Natl. Acad. Sci. USA 108: 7523-7528.
15. Takahashi, M., Y. Ishida, D. Iwaki, K. Kanno, T. Suzuki, Y. Endo, Y. Homma, and T. Fujita. 2010. Essential role of mannose-binding lectin-associated serine protease-1 in activation of the complement factor D. J. Exp. Med. 207: 29-37.
16. Degn, S. E., L. Jensen, A. G. Hansen, D. Duman, M. Tekin, J. C. Jensenius, and S. Thiel. 2012. Mannan-binding lectin-associated serine protease (MASP)-1 is crucial for lectin pathway activation in human serum, whereas neither MASP-1 nor MASP-3 is required for alternative pathway function. J. Immunol. 189: 3957-3969.
17. Sacks, S. H., and W. Zhou. 2012. The role of complement in the early immune response to transplantation. Nat. Rev. Immunol. 12: 431-442.
18. Oikonomopoulou, K., D. Ricklin, P. A. Ward, and J. D. Lambris. 2012. Interactions between coagulation and complement: their role in inflammation. Semin. Immunopathol. 34: 151-165.
19. Amara, U., M. A. Flierl, D. Rittirsch, A. Klos, H. Chen, B. Acker, U. B. Brückner, B. Nilsson, F. Gebhard, J. D. Lambris, and M. Huber-Lang. 2010. Molecular intercommunication between the complement and coagulation systems. J. Immunol. 185: 5628-5636.
20. Ritis, K., M. Doumas, D. Mastellos, A. Micheli, S. Giaglis, P. Magotti, S. Rafail, G. Kartalis, P. Sideras, and J. D. Lambris. 2006. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J. Immunol. 177: 4794-4802.
21. Krarup, A., R. Wallis, J. S. Presanis, P. Gál, and R. B. Sim. 2007. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS ONE 2: e623.
22. Endo, Y., N. Nakazawa, D. Iwaki, M. Takahashi, M. Matsushita, and T. Fujita. 2010. Interactions of ficolin and mannose-binding lectin with fibrinogen/fibrin augment the lectin complement pathway. J. Innate Immun. 2: 33-42.
23. Hamad, O. A., J. Bäck, P. H. Nilsson, B. Nilsson, and K. N. Ekdahl. 2012. Platelets, complement, and contact activation: partners in inflammation and thrombosis. Adv. Exp. Med. Biol. 946: 185-205.
24. Hajishengallis, G., and J. D. Lambris. 2010. Crosstalk pathways between Toll-like receptors and the complement system. Trends Immunol. 31: 154-163.
25. Carroll, M. C., and D. E. Isenman. 2012. Regulation of humoral immunity by complement. Immunity 37: 199-207.
26. Heeger, P. S., and C. Kemper. 2012. Novel roles of complement in T effector cell regulation. Immunobiology 217: 216-224.
27. Cardone, J., G. Le Friec, P. Vantourout, A. Roberts, A. Fuchs, I. Jackson, T. Suddason, G. Lord, J. P. Atkinson, A. Cope, et al. 2010. Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat. Immunol. 11: 862-871.
28. Han, G., S. Geng, Y. Li, G. Chen, R. Wang, X. Li, Y. Ma, B. Shen, and Y. Li. 2011. gdT-cell function in sepsis is modulated by C5a receptor signalling. Immunology 133: 340-349.
29. Kumar, V., S. R. Ali, S. Konrad, J. Zwirner, J. S. Verbeek, R. E. Schmidt, and J. E. Gessner. 2006. Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. J. Clin. Invest. 116: 512-520.
30. Karsten, C. M., M. K. Pandey, J. Figge, R. Kilchenstein, P. R. Taylor, M. Rosas, J. U. McDonald, S. J. Orr, M. Berger, D. Petzold, et al. 2012. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgRIIB and dectin-1. Nat. Med. 18: 1401-1406.
31. Ricklin, D., E. S. Reis, and J. D. Lambris. 2012. A sweet spot to control complement-induced inflammation. Nat. Med. 18: 1340-1341.
32. Fusakio, M. E., J. P. Mohammed, Y. Laumonnier, K. Hoebe, J. Köhl, and J. Mattner. 2011. C5a regulates NKT and NK cell functions in sepsis. J. Immunol. 187: 5805-5812.
33. Markiewski, M. M., R. A. DeAngelis, F. Benencia, S. K. Ricklin-Lichtsteiner, A. Koutoulaki, C. Gerard, G. Coukos, and J. D. Lambris. 2008. Modulation of the antitumor immune response by complement. Nat. Immunol. 9: 1225-1235.
34. Ali, H. 2010. Regulation of human mast cell and basophil function by anaphyla-toxins C3a and C5a. Immunol. Lett. 128: 36-45.
35. Anderson, D. H., M. J. Radeke, N. B. Gallo, E. A. Chapin, P. T. Johnson, C. R. Curletti, L. S. Hancox, J. Hu, J. N. Ebright, G. Malek, et al. 2010. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog. Retin. Eye Res. 29: 95-112.
36. Karagianni, N., and A. P. Adamis. 2010. The case for complement and inflammation in AMD: open questions. Adv. Exp. Med. Biol. 703: 1-7.
37. Weismann, D., K. Hartvigsen, N. Lauer, K. L. Bennett, H. P. Scholl, P. Charbel Issa, M. Cano, H. Brandstätter, S. Tsimikas, C. Skerka, et al. 2011. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 478: 76-81.
38. Lambert, J. C., and P. Amouyel. 2011. Genetics of Alzheimer's disease: new evidences for an old hypothesis? Curr. Opin. Genet. Dev. 21: 295-301.
39. Veerhuis, R., H. M. Nielsen, and A. J. Tenner. 2011. Complement in the brain. Mol. Immunol. 48: 1592-1603.
40. Fonseca, M. I., S. H. Chu, A. M. Berci, M. E. Benoit, D. G. Peters, Y. Kimura, and A. J. Tenner. 2011. Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease. J. Neuroinflammation 8: 4.
41. Fonseca, M. I., R. R. Ager, S. H. Chu, O. Yazan, S. D. Sanderson, F. M. LaFerla, S. M. Taylor, T. M. Woodruff, and A. J. Tenner. 2009. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J. Immunol. 183: 1375-1383.
42. Pickering, M., and H. T. Cook. 2011. Complement and glomerular disease: new insights. Curr. Opin. Nephrol. Hypertens. 20: 271-277.
43. Loirat, C., and V. Frémeaux-Bacchi. 2011. Atypical hemolytic uremic syndrome. Orphanet J. Rare Dis. 6: 60.
44. Noris, M., F. Mescia, and G. Remuzzi. 2012. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat. Rev. Nephrol. 8: 622-633.
45. Zuber, J., F. Fakhouri, L. T. Roumenina, C. Loirat, and V. Frémeaux-Bacchi; French Study Group for aHUS/C3G. 2012. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat. Rev. Nephrol. 8: 643-657.
46. Chen, M., M. R. Daha, and C. G. Kallenberg. 2010. The complement system in systemic autoimmune disease. J. Autoimmun. 34: J276-J286.
47. Holers, V. M. 2008. The spectrum of complement alternative pathway-mediated diseases. Immunol. Rev. 223: 300-316.
48. Karsten, C. M., and J. Köhl. 2012. The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases. Immunobiology 217: 1067-1079.
49. Chen, M., and C. G. Kallenberg. 2010. ANCA-associated vasculitides: advances in pathogenesis and treatment. Nat Rev Rheumatol 6: 653-664.
50. Schreiber, A., H. Xiao, J. C. Jennette, W. Schneider, F. C. Luft, and R. Kettritz. 2009. C5a receptor mediates neutrophil activation and ANCA-induced glomeru-lonephritis. J. Am. Soc. Nephrol. 20: 289-298.
51. Denny, K. J., T. M. Woodruff, S. M. Taylor, and L. K. Callaway. 2013. Complement in pregnancy: a delicate balance. Am. J. Reprod. Immunol. 69: 3-11.
52. Singh, J., A. Ahmed, and G. Girardi. 2011. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension 58: 716-724.
53. Qing, X., P. B. Redecha, M. A. Burmeister, S. Tomlinson, V. D. D'Agati, R. L. Davisson, and J. E. Salmon. 2011. Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int. 79: 331-339.
54. Lappas, M., T. M. Woodruff, S. M. Taylor, and M. Permezel. 2012. Complement C5A regulates prolabor mediators in human placenta. Biol. Reprod. 86: 190.
55. Girardi, G., J. Berman, P. Redecha, L. Spruce, J. M. Thurman, D. Kraus, T. J. Hollmann, P. Casali, M. C. Caroll, R. A. Wetsel, et al. 2003. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J. Clin. Invest. 112: 1644-1654.
56. Risitano, A. M. 2012. Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders. Immunobiology 217: 1080-1087.
57. Banz, Y., and R. Rieben. 2012. Role of complement and perspectives for intervention in ischemia-reperfusion damage. Ann. Med. 44: 205-217.
58. Gorsuch, W. B., E. Chrysanthou, W. J. Schwaeble, and G. L. Stahl. 2012. The complement system in ischemia-reperfusion injuries. Immunobiology 217: 1026-1033.
59. Nilsson, B., K. N. Ekdahl, and O. Korsgren. 2011. Control of instant blood-mediated inflammatory reaction to improve islets of Langerhans engraftment. Curr. Opin. Organ Transplant. 16: 620-626.
60. Rother, R. P., J. Arp, J. Jiang, W. Ge, S. J. Faas, W. Liu, D. R. Gies, A. M. Jevnikar, B. Garcia, and H. Wang. 2008. C5 blockade with conventional immunosuppression induces long-term graft survival in presensitized recipients. Am. J. Transplant. 8: 1129-1142.
61. Chen Song, S., S. Zhong, Y. Xiang, J. H. Li, H. Guo, W. Y. Wang, Y. L. Xiong, X. C. Li, S. Chen Shi, X. P. Chen, and G. Chen. 2011. Complement inhibition enables renal allograft accommodation and long-term engraftment in presensitized nonhuman primates. Am. J. Transplant. 11: 2057-2066.
62. Ekdahl, K. N., J. D. Lambris, H. Elwing, D. Ricklin, P. H. Nilsson, Y. Teramura, I. A. Nicholls, and B. Nilsson. 2011. Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategies. Adv. Drug Deliv. Rev. 63: 1042-1050.
63. Stahl, G. L., S. K. Shernan, P. K. Smith, and J. H. Levy. 2012. Complement activation and cardiac surgery: a novel target for improving outcomes. Anesth. Analg. 115: 759-771.
64. Lazar, H. L., T. Keilani, C. A. Fitzgerald, O. M. Shapira, C. T. Hunter, R. J. Shemin, H. C. Marsh, Jr., U. S. Ryan, and T. P. C. S. S. Group; TP10 Cardiac Surgery Study Group. 2007. Beneficial effects of complement inhibition with soluble complement receptor 1 (TP10) during cardiac surgery: is there a gender difference? Circulation 116(11, Suppl.): I83-I88.
65. Smith, P. K., S. K. Shernan, J. C. Chen, M. Carrier, E. D. Verrier, P. X. Adams, T. G. Todaro, L. H. Muhlbaier, and J. H. Levy; PRIMO-CABG II Investigators. 2011. Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. J. Thorac. Cardiovasc. Surg. 142: 89-98.
66. DeAngelis, R. A., E. S. Reis, D. Ricklin, and J. D. Lambris. 2012. Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis. Immunobiology 217: 1097-1105.
67. Kourtzelis, I., M. M. Markiewski, M. Doumas, S. Rafail, K. Kambas, I. Mitroulis, S. Panagoutsos, P. Passadakis, V. Vargemezis, P. Magotti, et al. 2010. Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood 116: 631-639.
68. Wu, Y. Q., H. Qu, G. Sfyroera, A. Tzekou, B. K. Kay, B. Nilsson, K. Nilsson Ekdahl, D. Ricklin, and J. D. Lambris. 2011. Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine. J. Immunol. 186: 4269-4277.
69. Zhang, X., and J. Köhl. 2010. A complex role for complement in allergic asthma. Expert Rev. Clin. Immunol. 6: 269-277.
70. Zhang, X., I. Schmudde, Y. Laumonnier, M. K. Pandey, J. R. Clark, P. König, N. P. Gerard, C. Gerard, M. Wills-Karp, and J. Köhl. 2010. A critical role for C5L2 in the pathogenesis of experimental allergic asthma. J. Immunol. 185: 6741-6752.
71. Marc, M. M., S. S. Kristan, A. Rozman, I. Kern, M. Flezar, M. Kosnik, and P. Korosec. 2010. Complement factor C5a in acute exacerbation of chronic obstructive pulmonary disease. Scand. J. Immunol. 71: 386-391.
72. Allison, A. C., and H. U. Schorlemmer. 1976. Activation of complement by the alternative pathway as a factor in the pathogenesis of periodontal disease. Lancet 308: 1001-1004.
73. Hajishengallis, G., and J. D. Lambris. 2012. Complement and dysbiosis in peri-odontal disease. Immunobiology 217: 1111-1116.
74. Abe, T., K. B. Hosur, E. Hajishengallis, E. S. Reis, D. Ricklin, J. D. Lambris, and G. Hajishengallis. 2012. Local complement-targeted intervention in periodontitis: proof-of-concept using a C5a receptor (CD88) antagonist. J. Immunol. 189: 5442-5448.
75. Breivik, T., Y. Gundersen, P. Gjermo, S. M. Taylor, T. M. Woodruff, and P. K. Opstad. 2011. Oral treatment with complement factor C5a receptor (CD88) antagonists inhibits experimental periodontitis in rats. J. Periodontal Res. 46: 643-647.
76. Schoengraf, P., J. D. Lambris, S. Recknagel, L. Kreja, A. Liedert, R. E. Brenner, M. Huber-Lang, and A. Ignatius. 2013. Does complement play a role in bone development and regeneration? Immunobiology 218: 1-9.
77. Barratt-Due, A., S. E. Pischke, O. L. Brekke, E. B. Thorgersen, E. W. Nielsen, T. Espevik, M. Huber-Lang, and T. E. Mollnes. 2012. Bride and groom in systemic inflammation: the bells ring for complement and Toll in cooperation. Immunobiology 217: 1047-1056.
78. Neher, M. D., S. Weckbach, M. A. Flierl, M. S. Huber-Lang, and P. F. Stahel. 2011. Molecular mechanisms of inflammation and tissue injury after major trauma: is complement the "bad guy"? J. Biomed. Sci. 18: 90.
79. Bosmann, M., and P. A. Ward. 2012. The inflammatory response in sepsis. Trends Immunol. 34: 129-136.
80. Markiewski, M. M., and J. D. Lambris. 2009. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol. 30: 286-292.
81. Glennie, M. J., R. R. French, M. S. Cragg, and R. P. Taylor. 2007. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44: 3823-3837.
82. Beurskens, F. J., M. A. Lindorfer, M. Farooqui, P. V. Beum, P. Engelberts, W. J. Mackus, P. W. Parren, A. Wiestner, and R. P. Taylor. 2012. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J. Immunol. 188: 3532-3541.
83. Kolev, M., L. Towner, and R. Donev. 2011. Complement in cancer and cancer immunotherapy. Arch. Immunol. Ther. Exp. (Warsz.) 59: 407-419.
84. Corrales, L., D. Ajona, S. Rafail, J. J. Lasarte, J. I. Riezu-Boj, J. D. Lambris, A. Rouzaut, M. J. Pajares, L. M. Montuenga, and R. Pio. 2012. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J. Immunol. 189: 4674-4683.
85. Nunez-Cruz, S., P. A. Gimotty, M. W. Guerra, D. C. Connolly, Y.-Q. Wu, R. A. DeAngelis, J. D. Lambris, G. Coukos, and N. Scholler. 2012. Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia 14: 994-1004.